Infectious Disease Surveillance Center. Infectious Agents Surveillance Report 29(10), October 2008. Available at: http://idsc.nih.go.jp/iasr/29/344/tpc344.html. Accessed 6 November 2009.
Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry J, Demmler GJ, Kaplan K, editors. Text book of pediatric infectious diseases. 5th ed. Philadelphia: W B Saunders; 2004. p. 2315–41.
Tsutsumi H. Respiratory syncytial virus infection. Kansenshogaku Zasshi. 2005;79:857–63 (In Japanese).
American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CF, Long SS, McMillian JA, editors. Red Book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village: American Academy of Pediatrics; 2006. p. 560.
The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–40.
Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transpl. 1995;16:393–9.
Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–82.
Pohl C, Green M, Wald E, Ledesma-Medina J. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis. 1992;165:166–9.
Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143:S112–7.
Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22:S40–5.
Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J Pediatr Hematol Oncol. 2007;29:227–32.
American Society of Transplantation.Community-acquired respiratory viruses. Am J Transplant. 2004; Suppl 10:105–9.
Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis––a prospective birth-cohort study. Pediatrics. 2007;120:e1076–81.
Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int. 2006;48:190–3.
Aoki T, Tsutsumi H, Takeuchi Y. Epidemiology of respiratory syncytial virus infection in Japan. Nippon Shonika Gakkai Zasshi. 2008;112:1067–75 (In Japanese).
Sasaki N, Matayoshi K, Kise T, Shimabukuro M, Isa M. The epidemiology and clinical features of patients with respiratory syncytial virus infection in Okinawa. Nippon Shonika Gakkai Zasshi. 2006;110:668–73 (In Japanese).
Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Palivizumab Outcomes Registry Group Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511–7.
Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26:485–91.
Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young. 2003;13:420–3.
Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child. 2009;94:99–103.
Ministry of Health and Long-Term Care. Process for requesting Synagis™ (palivizumab) for infants in the 2008–2009 respiratory syncytial virus (RSV) season in the province of Ontario. Available at: http://www.pcch.on.ca/pdf/letter%20v6%20final%2020080908.pdf. Accessed 6 November 2009.
Tufts Health Plan. Pharmacy Medical Necessity Guidelines. Available at: http://www.tuftshealthplan.com/providers/pdf/pharmacy_criteria/Synagis.pdf. Accessed 6 November 2009.
Medco Health Solutions, Inc. Respiratory Syncytial Virus Agents. Available at: http://provider.medmutual.com/pdf/RSVagent.pdf. Accessed 6 November 2009.
Medicaid Enterprise Iowa Department of Human Services. Prescribed drugs provider manual. Available at: http://www.dhs.state.ia.us/PolicyAnalysis/PolicyManualPages/Manual_Documents/Provman/drugs.pdf. Accessed 6 November 2009.
Blue Cross Blue Shield of Massachusetts. Policy #422: RSV Immunoprophylaxis. Available at: http://www.bluecrossma.com/common/en_US/medical_policies/422%20RSV%20Immunoprophylaxis%20prn.pdf. Accessed 6 November 2009.